Technology Core

摘要： 全球床旁（POC）检测市场预计将每年增长12%，到2030年将超过900亿美元。司机 市场增长包括新出现的疾病威胁，自我检测需求的增加，成功的市场塑造 干预措施，低收入和中等收入国家（LMIC）对基本诊断的需求不断增加， 医疗分权现在，POC每年进行超过10亿次COVID-19检测， 大流行检测反应表明：新一代高性能，负担得起的分子检测可以 制造、分发和快速适应新目标;广大用户可以准确地执行家庭 测试;测试结果可以在需要时进行快速治疗。POCTRN网络为此做出了重大贡献。 成功。尽管RADx的成功和新冠病毒POC检测的快速规模，但仍存在一些重大障碍 然而，我们仍然需要发挥POC检测的潜力，特别是在癌症的早期检测方面。The Technology的使命 公平癌症护理床旁技术创新和转化中心（CITEC）的核心是 加入POCTRN，支持和加速高优先级POC技术的开发和转化，特别是 专为癌症筛查和早期发现服务不足的人群。技术核心（TC）的第一个目标 是识别和支持新的有价值的项目，以开发用于癌症筛查或早期癌症的POC技术 从原型到早期临床测试的检测。过渡委员会将与传播核心合作， 评估，以确定癌症筛查和早期发现的高度优先的未满足的临床需求，随后， 发布共识POC技术需求声明。CITEC将发布有针对性的招标，提供资金，以解决 这些需求。技术合作将支持专门为服务不足社区设计的技术项目，包括 旨在解决与癌症健康差异和低资源环境相关的挑战和障碍（例如，农村 设置，基础设施有限的设置）。技术委员会的第二个目标是协助受支持的POC技术开发人员 完善其临床需求声明，包括目标测试规范，并完善和评估技术性能， 其技术的可用性和可制造性，目的是加快转化和临床的道路 领养技术委员会将建立CITEC核心技术实验室，拥有独特和全面的技术资源， 支持POC成像技术、POC分子传感器和机器的设计、制造和快速优化 适合于移动的平台的基于学习的图像分析策略。TC的第三个目标是帮助翻译 有前途的原型临床验证和商业化。TC将与临床核心密切合作， 为临床评价做好准备的技术，并支持在相关临床环境中过渡到评价。的TC 我将与POC测试开发人员合作，加快开发商业原型的努力，并开发成功的 商业化战略，利用得克萨斯州医疗中心和巴西的资源。通过这些目标，TC 我将与CITEC的其他核心合作，建立和支持一个强大的POC技术管道，以实现公平的癌症筛查 及早发现。

Abstract: The global market for point‐of‐care (POC) tests is projected to grow 12% annually, exceeding US$90B by 2030. Drivers of market growth include emerging disease threats, increasing demand for self‐testing, successful market shaping interventions, increasing demand for essential diagnostics in low‐ and middle‐income countries (LMICs), and a trend for health‐care decentralization. More than a billion COVID‐19 tests are now performed annually at the POC, and the pandemic testing response demonstrated that: a new generation of high performance, affordable molecular tests can be manufactured, distributed, and rapidly adapted for new targets; a broad segment of users can accurately perform home testing; and test results can enable rapid treatment when needed. The POCTRN network contributed significantly to these successes. Despite the success of RADx and the rapid scale of POC testing for COVID, a number of significant barriers still remain to achieve the potential of POC testing, especially for the early detection of cancer. The mission of The Technology Core of The Center for Innovation and Translation of Point‐of‐Care Technologies for Equitable Cancer Care (CITEC) is to join POCTRN in supporting and accelerating the development and translation of high priority POC technologies specifically designed for cancer screening and early detection for under‐served populations. The first aim of the Technology Core (TC) is to identify and support new meritorious projects to develop POC technologies for cancer screening or early cancer detection from prototype through early clinical testing. In collaboration with the Dissemination Core, the TC will conduct assessments to identify high priority unmet clinical needs for cancer screening and early detection, and, subsequently, publish consensus POC Technology Needs Statements. CITEC will issue targeted solicitations offering funding to address these needs. The TC will support technology projects specifically designed for underserved communities, including those designed to address challenges and barriers associated with cancer health disparities and low‐resource settings (e.g., rural settings, settings with limited infrastructure). The second aim of the TC is to assist supported POC technology developers to refine their clinical needs statement, including target test specifications, and refine and assess technical performance, usability, and manufacturability of their technology, with the objective of accelerating the path to translation and clinical adoption. The TC will create a CITEC Core Technology Laboratory with unique and comprehensive technical resources to support the design, fabrication and rapid optimization of POC imaging technologies, POC molecular sensors, and machine learning based image analysis strategies appropriate for mobile platforms. The third aim of the TC is to help translate promising prototypes to clinical validation and commercialization. The TC will work closely with the Clinical Core to identify technologies ready for clinical evaluation and to support the transition to evaluation in relevant clinical settings. The TC will work with POC test developers to accelerate efforts to develop commercial prototypes and to develop successful commercialization strategies, leveraging resources in the Texas Medical Center and in Brazil. Through these aims, the TC will work with other CITEC cores to build and support a robust pipeline of POC technologies for equitable cancer screening and early detection.